Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – What’s Next?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped up prior to trading on Thursday . The stock had previously closed at $18.02, but opened at $18.91. Daiichi Sankyo shares last traded at $18.2650, with a volume of 9,132 shares changing hands.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DSNKY. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Zacks Research lowered Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Down 1.4%

The firm has a market cap of $33.55 billion, a price-to-earnings ratio of 20.94, a PEG ratio of 2.51 and a beta of -0.11. The company has a quick ratio of 1.64, a current ratio of 2.92 and a debt-to-equity ratio of 0.29. The firm has a fifty day moving average price of $17.28 and a 200-day moving average price of $17.34.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, sell-side analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 EPS for the current year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.